Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
NCT ID: NCT04912687
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
580 participants
INTERVENTIONAL
2022-01-01
2027-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
NCT03562819
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT07028489
Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
NCT01525199
Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
NCT01167972
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
NCT03721289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both tissue and liquid biopsy samples will follow usual processes and will be sent to the Molecular Pathology laboratory of the Investigation center.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All patients
For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.
As per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample.
EGFR gene mutation analysis on liquid biopsy
Blood samples will be collected at inclusion for plasma DNA collection and analysis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EGFR gene mutation analysis on liquid biopsy
Blood samples will be collected at inclusion for plasma DNA collection and analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed non-small cell lung carcinoma,
3. No previous treatment for NSCLC,
4. Indication to EGFR status determination following HAS recommendation,
5. Voluntary signed and dated written informed consent prior to any study specific procedure
6. Patients with a social security in compliance with the French Law.
Exclusion Criteria
2. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Institut Bergonié
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, , France
Institut Bergonie
Bordeaux, , France
CHRU Lille
Lille, , France
Hospices Civils de Lyon
Lyon, , France
CHU Nice-Hopital de Cimiel
Nice, , France
Institut Curie
Paris, , France
CHU Poitiers
Poitiers, , France
CHU de Rennes - Hopital Pontchaillou
Rennes, , France
CHU Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A00685-36
Identifier Type: OTHER
Identifier Source: secondary_id
IB 2021-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.